Choose your country

Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic

Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month SEOUL, Korea (April 12, 2021) – Seegene Inc. (KQ 096530), a biotechnology company specia...

Seegene supports Mexico’s ‘back to school’ campaign with COVID-19 tests and face masks

South Korea’s leading molecular diagnostics firm Seegene Inc. (KQ096530) said Friday it is supporting the Mexican government’s push to return life to pre-pandemic days. During a ceremonial event...

Seegene Announces Submission to U.S. FDA for Emergency Use Authorization of Its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay

Real-time test differentiates influenza A & B, RSV and COVID-19SEOUL, South Korea (March 1, 2021)— Seegene Inc., (KQ096530), a biotechnology company specializing in molecular diagnostics, has s...

Seegene’s Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants

- Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min - Seegene’s proprietary high multiplex technology enables detection of 10 different targets - S. K...

Seegene’s saliva test for COVID-19 is just as effective as NPS test

A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen. A research team at the Department of Laboratory Medicine ...

Seegene develops world first COVID-19 variant test capable of identifying origins of virus variants

- SEEGENE ROLLS OUT FIRST COVID-19 MUTANT IDENTIFICATION TEST - COVID-19 TEST MANUFACTURER CONTINUES TRACKING VARIANTS - S. KOREAN FIRM COMMITTED TO WORKING WITH GOVERNMENTS South Korea’s...

Seegene to advance business in Latin America in the New Year

South Korea’s leading molecular diagnostics firm Seegene Inc. (KQ096530) said Wednesday that it is expanding its business in Latin America in the new year with a strong focus on its multiplex assay ...

Seegene’s COVID-19 test with saliva sample collection feature now available in Europe

South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2...

Seegene donates 20,000 COVID-19 tests to Ecuador

Seegene Inc. (KQ096530), a South Korean biotechnology company specializing in molecular diagnostics says it has donated 20,000 COVID-19 tests (Allplex™ SARS-CoV-2 Assay) to Ecuadorian government to he...

Seegene’s aggregated sales surpass KRW 1 tril. this year; plans on expanding annual production capacity to KRW 5 tril. in 2021

South Korea’s biotechnology company specializing in molecular diagnosis, Seegene Inc. (KQ096530), announced Monday that its aggregated sales this year have already surpassed the KRW 1 trillion mark,...

Seegene’s COVID-19/FluA,B/RSV test with extraction-free feature now available in Europe

South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Thursday that the extraction-free application of Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is no...

Global biotech firm Seegene posts a record high in Q3 sales

Seegene Inc. (KQ096530), a biotechnology company specializing in molecular diagnostics, headquartered in South Korea, reported a record high in sales revenue of KRW 326.9 billion and an operating pr...

Seegene introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COVID-19 with dual internal controls

Seegene Exports 10 million Corona Tests to Brazil

Seegene to secure a bridgehead for leading MDx market in Latin AmericaSEOUL, Korea, May 5, 2020 – Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered in South Kor...